Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
This study has been completed.
Ohio State University Comprehensive Cancer Center
Information provided by (Responsible Party):
Craig Hofmeister, Ohio State University Comprehensive Cancer Center
First received: September 12, 2005
Last updated: June 9, 2015
Last verified: June 2015
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||March 2008|
|Primary Completion Date:||August 2006 (Final data collection date for primary outcome measure)|
Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant. 2008 Jul;14(7):783-9. doi: 10.1016/j.bbmt.2008.04.006.